Literature DB >> 31337527

Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential-a prospective multi-centric study.

Aditi Bhatt1, Yutaka Yonemura2, Nazim Benzerdjeb3, Sanket Mehta4, Suniti Mishra5, Loma Parikh6, Praveen Kammar4, Mita Y Shah7, Aruna Prabhu8, Sakina Shaikh9, Mahesh D Patel9, Sylvie Isaac3, Olivier Glehen10.   

Abstract

BACKGROUND AND AIM: The grade/histological subtype is one of the most important prognostic markers in patients undergoing cytoreductive surgery (CRS). Our aim was to study other potential prognostic information that can be derived from the pathological evaluation of CRS specimens and provide a broad outline for evaluation of these.
METHODS: This prospective study (July to December 2018) included all patients undergoing cytoreductive surgery (CRS). A protocol for pathological evaluation was laid down which was based on existing practices at the participating centers and included evaluation of the pathological PCI, regional node involvement, response to chemotherapy, morphology of peritoneal metastases (PM) and distribution in the peritoneal cavity.
RESULTS: In 191 patients undergoing CRS at 4 centers, the pathological and surgical PCI differed in over 75%. Nodes in relation to peritoneal disease were positive in 13.6%. Disease in normal peritoneum adjacent to tumor nodules was seen in >50% patients with ovarian cancer and mucinous apppendiceal tumors. 23.8% of evaluated colorectal PM patients had a complete response and 25.0% ovarian cancer patients had a near complete pathological response to chemotherapy.
CONCLUSIONS: Pathological evaluation of extent and distribution of peritoneal disease differs from the surgical evaluation in majority of the patients. Lymph node involvement in relation of peritoneal disease is common. The morphological presentation of PM in ovarian cancer and mucinous appendiceal tumors merits evaluation of more extensive resections in these patients. Standardized methods of synoptic reporting of CRS specimens could help capture vital prognostic information that may in future influence how these patients are treated.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Cytoreductive surgery; Lymph node metastases; Pathological PCI; Pathological evaluation; Peritoneal metastases; Synoptic reporting

Mesh:

Year:  2019        PMID: 31337527     DOI: 10.1016/j.ejso.2019.07.019

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

1.  Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience.

Authors:  Fabio Carboni; Orietta Federici; Isabella Sperduti; Settimio Zazza; Domenico Sergi; Francesco Corona; Mario Valle
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

2.  Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer.

Authors:  Aditi Bhatt; Snita Sinukumar; Vahan Kepenekian; Praveen Kammar; Sanket Mehta; Sakina Shaikh; Witold Gertych; Naoual Bakrin; Olivier Glehen
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

3.  Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study.

Authors:  Aditi Bhatt; Pascal Rousset; Dario Baratti; Daniele Biacchi; Nazim Benzerdjeb; Ignace H J T de Hingh; Marcello Deraco; Vadim Gushchin; Praveen Kammar; Daniel Labow; Edward Levine; Brendan Moran; Faheez Mohamed; David Morris; Sanket Mehta; Aviram Nissan; Mohammad Alyami; Mohammad Adileh; Shoma Barat; Almog Ben Yacov; Kurtis Campbell; Kathleen Cummins-Perry; Delia Cortes-Guiral; Noah Cohen; Loma Parikh; Samer Alammari; Galal Bashanfer; Anwar Alshukami; Kaushal Kundalia; Gaurav Goswami; Vincent van de Vlasakker; Michelle Sittig; Paolo Sammartino; Armando Sardi; Laurent Villeneuve; Kiran Turaga; Yutaka Yonemura; Olivier Glehen
Journal:  BMJ Open       Date:  2021-07-05       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.